top of page

GLP1s (Semaglutide/Trizepatide) Reduce Alcohol/Opioid Abuse risk by 50%

Unlocking New Benefits of Weight-Loss Medications: A 50% Reduction in Substance Abuse


Recent studies have revealed that weight-loss medications like Semaglutide and Tirzepatide, which are already popular for their effectiveness in managing diabetes and obesity, offer even more incredible benefits. These medications can reduce rates of opioid and alcohol abuse by up to 50%!



The mechanism behind this dual benefit lies in the way these drugs mimic gut hormones to control blood sugar levels and reduce appetite. Novo Nordisk’s Wegovy and Ozempic, along with Eli Lilly’s Mounjaro, are leading the charge in this innovative approach to health management. These medications have been approved in the U.S. and Europe for treating diabetes and obesity, and their popularity has soared, leading to shortages due to high demand3.


The study’s authors emphasize the importance of making these effective treatments readily available to those who could benefit.

A

t our clinic, we are committed to providing you with the best tools and support for your weight loss journey. If you’re ready to explore how these groundbreaking medications can help you achieve your health goals and reduce the risk of substance abuse, we invite you to sign up for our services today. Together, we can unlock a healthier, happier future!


Join us now and take the first step towards a transformative health journey!


Full article that I'm summarized above available here: msn.com


Pacific Northwest Medical Group

6622 112th ST E, Puyallup WA 98373

253-340-2270




bottom of page